Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study

Clin Infect Dis. 2017 May 1;64(9):1275-1278. doi: 10.1093/cid/cix125.

Abstract

We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.

Keywords: coinfection; hepatitis delta virus; human immunodeficiency virus; replication; tenofovir.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Cohort Studies
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • Hepatitis B virus / isolation & purification
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / virology
  • Hepatitis D / virology*
  • Hepatitis Delta Virus / drug effects*
  • Hepatitis Delta Virus / isolation & purification
  • Hepatitis Delta Virus / physiology
  • Humans
  • Male
  • Middle Aged
  • Switzerland
  • Tenofovir / therapeutic use*
  • Viral Load
  • Virus Replication / drug effects*

Substances

  • Anti-HIV Agents
  • Tenofovir